Traws Pharma, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Traws Pharma, Inc. (TRAW) has filed its Q1 2024 10-Q report, detailing financial positions and equity instruments.</b>

AI Summary

Traws Pharma, Inc. (TRAW) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Traws Pharma, Inc. (TRAW) filed a 10-Q report for the period ending March 31, 2024. The company was formerly known as Onconova Therapeutics, Inc. The filing includes data related to common stock, preferred stock, and retained earnings as of March 31, 2024. Information on employee stock options and various restricted stock units (RSUs) is also present. The filing covers the period from January 1, 2024, to March 31, 2024.

Why It Matters

For investors and stakeholders tracking Traws Pharma, Inc., this filing contains several important signals. This 10-Q filing provides an updated snapshot of Traws Pharma's financial health and equity structure as of the first quarter of 2024. Understanding the details of common stock, preferred stock, and stock-based compensation plans is crucial for investors assessing the company's capital structure and potential dilution.

Risk Assessment

Risk Level: low — Traws Pharma, Inc. shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain significant new financial data or strategic shifts that would indicate high risk.

Analyst Insight

Investors should review the detailed equity information and retained earnings to understand the company's financial standing and capital structure.

Financial Highlights

revenue

21043458

total Assets

21003409

net Income

21085935

eps

0.28

revenue Growth

0.24

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-01-01 — Quarter Start Date (10-Q filing)
• 2023-03-31 — Prior Year Period End Date (10-Q filing)
• 2023-01-01 — Prior Year Quarter Start Date (10-Q filing)

Key Players & Entities

• Traws Pharma, Inc. (company) — Filer name
• TRAW (company) — Ticker symbol
• Onconova Therapeutics, Inc. (company) — Former company name
• 2024-03-31 (date) — Reporting period end date
• 2024-05-15 (date) — Filing date

FAQ

Risk Factors

• General Risk Factors [medium — regulatory]: The company is subject to the risks and uncertainties inherent in the pharmaceutical industry, including regulatory hurdles and market acceptance of its products.

Key Dates

• 2024-03-31: Quarterly Period End — Financial data as of this date is reported.
• 2024-05-15: Filing Date — The 10-Q report was officially submitted.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides an update on the company's financial performance and condition between annual reports.)

Common Stock

A security that represents ownership in a corporation. (Key component of the company's capital structure, detailed in the filing.)

Preferred Stock

A class of ownership in a corporation that has a higher claim on assets and earnings than common stock. (Indicates different classes of ownership and their rights, as detailed in the filing.)

Retained Earnings

The cumulative amount of net income of a corporation that has not been distributed as dividends. (Reflects the company's historical profitability and dividend policy.)

Key Financial Figures

• $0.01 — he registrant's Common Stock, par value $0.01 per share, as of May 1, 2024 was 25,301

Filing Documents

• tmb-20240331x10q.htm (10-Q) — 938KB
• tmb-20240331xex10d5.htm (EX-10.5) — 102KB
• tmb-20240331xex31d1.htm (EX-31.1) — 10KB
• tmb-20240331xex31d2.htm (EX-31.2) — 10KB
• tmb-20240331xex32d1.htm (EX-32.1) — 6KB
• tmb-20240331xex32d2.htm (EX-32.2) — 6KB
• 0001558370-24-008326.txt (&nbsp;) — 4652KB
• tmb-20240331.xsd (EX-101.SCH) — 33KB
• tmb-20240331_cal.xml (EX-101.CAL) — 29KB
• tmb-20240331_def.xml (EX-101.DEF) — 142KB
• tmb-20240331_lab.xml (EX-101.LAB) — 311KB
• tmb-20240331_pre.xml (EX-101.PRE) — 244KB
• tmb-20240331x10q_htm.xml (XML) — 698KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Consolidated Statement of Stockholders' Equity (Deficit) 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 28

Controls and Procedures

Item 4. Controls and Procedures 28

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 30

Risk Factors

Item 1A. Risk Factors 30

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 33

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 33

Other Information

Item 5. Other Information 33

Exhibits

Item 6. Exhibits 34

SIGNATURES

SIGNATURES 35 2 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Traws Pharma, Inc. Condensed Consolidated Balance Sheets March 31, December 31, 2024 2023 Assets (unaudited) Current assets: Cash and cash equivalents $ 16,390,000 $ 20,821,000 Receivables 18,000 18,000 Prepaid expenses and other current assets 1,745,000 1,821,000 Total current assets 18,153,000 22,660,000 Property and equipment, net 18,000 22,000 Other non-current assets 1,000 1,000 Total assets $ 18,172,000 $ 22,683,000 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 6,568,000 $ 5,619,000 Accrued expenses and other current liabilities 2,628,000 3,375,000 Deferred revenue 226,000 226,000 Total current liabilities 9,422,000 9,220,000 Deferred revenue, non-current 2,735,000 2,791,000 Total liabilities 12,157,000 12,011,000 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.01 par value, 5,000,000 shares authorized, none issued and outstanding at March 31, 2024 and December 31, 2023 — — Common stock, $ 0.01 par value, 125,000,000 shares authorized, 21,085,935 and 21,003,409 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 211,000 210,000 Additional paid in capital 493,448,000 493,116,000 Accumulated deficit ( 487,614,000 ) ( 482,631,000 ) Accumulated other comprehensive loss ( 30,000 ) ( 23,000 ) Total stockholders' equity 6,015,000 10,672,000 Total liabilities and stockholders' equity $ 18,172,000 $ 22,683,000 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents Traws Pharma, Inc. Condensed Consolidated Statements of Operations (unaudited) Three Months Ended March 31, 2024 2023 Revenue $ 56,000 $ 56,000 Operating expenses: General and administrative 3,356,000 2,113,000 Research and development 1,912,000 4,080,000 Total operating expenses 5,268,000 6,193,000

View Full Filing

View this 10-Q filing on SEC EDGAR